Abstract:Although a clear mechanism underlying the pathophysiology of schizophrenia (SZ) remains elusive, oxidative stress, inflammatory syndrome and immune activation have become an attractive hypothesis for explaining the pathophysiology of SZ. Data from prior studies on the role of matrix metalloproteinase 9 (MMP-9) and brain-derived neurotrophic factor (BDNF) single nucleotide polymorphisms (SNPs) in SZ are contradictory. We aimed to investigate whether oxidative stress, inflammatory and immune activation markers as well as MMP-9 levels may be implicated in SZ pathogenesis. The association of MMP-9 and BDNF SNPs with the clinical expression of SZ was examined.Ninety-four subjects were recruited, including 44 SZ patients and 50 healthy controls. Serum levels of thiobarbituric acid reactive substances (TBARS), protein carbonyl content (PCC), nitrite, C-reactive protein (CRP), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), Beta-2 microglobulin (Β2M), complement component 3 (C3), C4 and MMP-9 were measured. The MMP-9 − 1562C > T and BDNF196G > A SNPs were genotyped using polymerase chain reaction-restriction fragment length polymorphism assay. Psychopathology was assessed using the positive and negative syndrome scale (PANSS).SZ patients showed significantly higher TBARS, PCC, nitrite, CRP, IL-6, TNF-α, Β2M, C3 and MMP-9 levels than controls. In distinguishing SZ patients from healthy controls, CRP and MMP-9 yielded similar discriminatory performance, and both perform better than IL-6, Β2M, C3, nitrite, TBARS, PCC, TNF-α and C4. The MMP-9 − 1562C > T SNP genotypes distribution didn't differ significantly between controls and SZ patients. As compared to controls, SZ patients harbor a significantly higher frequency of the BDNF196GG genotype and a lower frequency of the BDNF196GA/AA genotype. Patients carrying the MMP-9 − 1562CC or BDNF196GG genotype revealed a significantly higher PANSS than those carrying MMP-9 − 1562CT/TT or BDNF196GA/AA genotype. Male gender and the MMP-9 − 1562CC genotype were identified as independent predictive factors for higher PANSS.Redox dysregulation and alterations in the immuno-inflammatory pathways are major culprits in the pathogenesis of SZ. MMP-9 and BDNF SNPs are associated with the clinical phenotype of SZ and, thus, may be a useful marker predicting the phenotypic expression and prognosis of SZ patients.

Association between elevated serum matrix metalloproteinase-2 and tumor necrosis factor-α, and clinical symptoms in male patients with treatment-resistant and chronic medicated schizophrenia

The C(−1562)T Polymorphism of Matrix Metalloproteinase-9 Gene is Associated with Schizophrenia in China

Sex Differences in the Association of Treatment-Resistant Schizophrenia and Serum Interleukin-6 Levels

Catalase and interleukin-6 serum elevation in a prediction of treatment-resistance in male schizophrenia patients

The Level of Serum Matrix Metalloproteinase-3 and Its Significance in Patients with Ankylosing Spondylitis

Differences in Inflammatory Marker Profiles and Cognitive Functioning Between Deficit and Nondeficit Schizophrenia

Decreased Serum TNF-alpha Levels in Chronic Schizophrenia Patients on Long-Term Antipsychotics: Correlation with Psychopathology and Cognition

Potential role between inflammatory cytokines and Tie-2 receptor levels and clinical symptoms in patients with first-episode schizophrenia

Variations of plasma oxidative stress levels in male patients with chronic schizophrenia. Correlations with psychopathology and matrix metalloproteinase-9: a case-control study

Immunoinflammatory features and cognitive function in treatment-resistant schizophrenia: unraveling distinct patterns in clozapine-resistant patients

Relationship between plasma TNF-α levels and agitation symptoms in first episode patients with schizophrenia

Elevated plasma matrix metalloproteinase 9 in schizophrenia patients associated with poor antipsychotic treatment response and white matter density deficits

Reduced serum TNF alpha level in chronic schizophrenia patients with or without tardive dyskinesia.

Relationship between TNF-α levels and psychiatric symptoms in first-episode drug-naïve patients with schizophrenia before and after risperidone treatment and in chronic patients

Temporal Changes in Brain Morphology Related to Inflammation and Schizophrenia: an Omnigenic Mendelian Randomization Study.

The Role of Cytokines in Predicting the Efficacy of Acute Stage Treatment in Patients with Schizophrenia

Inflammatory disequilibrium and lateral ventricular enlargement in treatment-resistant schizophrenia

Variations in inflammatory regulators in male patients with chronic schizophrenia associated with psychopathology and cognitive deficits

Correlation of Serum High-Sensitivity C-Reactive Protein, Homocysteine, and Macrophage Migration Inhibitory Factor Levels With Symptom Severity and Cognitive Function in Patients With Schizophrenia

Elevated Interleukin-18 Serum Levels in Chronic Schizophrenia: Association with Psychopathology

Variations to plasma H 2 O 2 levels and TAC in chronical medicated and treatment-resistant male schizophrenia patients: Correlations with psychopathology